Xbi stock price forecast the three-month "xbi stock price

The three-month "xbi stock price forecast" is boosted by sector rotation patterns, suggesting that biotech ETFs could outperform broader healthcare indexes amid anticipated Q3 data releases. In Q3 2023 , revenue was $45.6 million, up 19.1% from $38.3 million a year earlier. Its nine-month revenue was $132.5 million, up 19.3% from a year ago. More importantly, it expects to generate gross margins near 70% in 2023 with an adjusted EBITDA margin in the mid-teens. Six analysts cover its stock and five rate it a Buy, with a $42 target price. Vericel is great a biotech stock to buy for do-it-yourself investors considering this area of the market. The S&P 500 fell 0.63%, while the Nasdaq Composite slipped 0.98%. The Dow Jones Industrial Average pulled back 113 points, or 0.25%. Traders following the "xbi stock price forecast" note correlation shifts with Nasdaq biotech indices, potentially leading to stronger performance during risk-on cycles.